Cost Management Insights: SG&A Expenses for Amgen Inc. and Intra-Cellular Therapies, Inc.

Cost Management Insights: SG&A Expenses for Amgen Inc. and Intra-Cellular Therapies, Inc.

In the ever-evolving pharmaceutical industry, effective cost management is crucial for maintaining competitive advantage. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Amgen Inc. and Intra-Cellular Therapies, Inc., from 2014 to 2023.

Amgen Inc.

Amgen Inc., a leader in biotechnology, has seen its SG&A expenses grow by approximately 31% over the past decade. Starting at $4.7 billion in 2014, these expenses peaked at $6.2 billion in 2023, reflecting strategic investments in marketing and administration.

Intra-Cellular Therapies, Inc.

In contrast, Intra-Cellular Therapies, Inc., a smaller player, experienced a staggering 3,860% increase in SG&A expenses, from $10 million in 2014 to $410 million in 2023. This surge underscores the company's aggressive expansion and market penetration strategies.

Understanding these trends offers valuable insights into the financial strategies of these pharmaceutical giants.